Associations between the LEP -2548G/A Promoter and Baseline Weight and between LEPR Gln223Arg and Lys656Asn Variants and Change in BMI z Scores in Arab Children and Adolescents Treated with Risperidone.

Noor B Almandil,Rohit J Lodhi,Hongyan Ren,Frank M C Besag,David Rossolatos,Ruth Ohlsen,Caitlin Slomp,Diego L Lapetina, Giona Plazzotta,Macey L Murray, Abdulsalam A Al-Sulaiman,Paul Gringras,Ian C K Wong,Katherine J Aitchison

Molecular neuropsychiatry（2018）

引用 3|浏览4

暂无评分

摘要

Data on baseline (antipsychotics-naïve) age, weight, and height, and change in these at 3 subsequent follow-up time points up to 313.6 days (95% CI 303.5-323.7) were collected from 181 risperidone-treated children and adolescents (mean age 12.58 years, SD 4.99, range 2.17-17.7) attending a pediatric neurology clinic in Saudi Arabia. Owing to differences in genotypic distributions in the subsamples, results are reported for the white Arab population ( nzzzzLEPLEPRHTR2Cpppz

查看译文

关键词

Adolescent,Antipsychotic agents,Biomarker,Child,Genetics,Leptin,Leptin receptor,Pharmacogenetics,Polymorphism,Weight gain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要